The European Union Launches Its Largest Clinical Investment in Phage Therapy Against Antibiotic-Resistant Infections

-

Antimicrobial resistance (AMR) has become one of the greatest threats to modern medicine. According to the World Health Organization, bacterial pathogens resistant to antibiotics are responsible for an increasing number of deaths worldwide and threaten decades of medical progress. Chronic wound infections, recurrent urinary tract infections, prosthetic joint infections and numerous healthcare-associated infections are becoming progressively more difficult to treat as conventional antibiotics lose their effectiveness. Recognising the urgency of the situation, the United Nations General Assembly identified antimicrobial resistance as a global health emergency in 2016, while the World Health Organization continues to rank AMR among the ten leading threats to global health.

©The Phage Therapy

Against this backdrop, the European Union has launched its most ambitious funding initiative dedicated to clinical phage therapy to date. Through the Horizon Europe topic "Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections", the European Commission has invested more than €45.6 million to generate the high-quality clinical evidence required to move bacteriophage therapy closer to routine medical practice.

Unlike previous research programmes that largely focused on laboratory development or compassionate-use experiences, this call was specifically designed to support large multinational randomized controlled clinical trials capable of demonstrating both the safety and efficacy of therapeutic bacteriophages under rigorous regulatory standards.

The objective is clear: transform phage therapy from a promising experimental approach into an evidence-based medical treatment supported by robust clinical data.

The European Commission recognizes that phage therapy has already shown encouraging results in numerous compassionate-use cases and several early clinical studies. However, despite decades of scientific interest, relatively few randomized controlled trials have been completed, and those conducted so far have often involved limited numbers of patients or have faced logistical and manufacturing challenges. One of the explicit objectives of this call is therefore to learn from previous experiences, including unsuccessful trials such as PhagoBurn, in order to improve future study design, patient selection, phage production, treatment protocols and clinical endpoints.

Importantly, the call does not favor one therapeutic philosophy over another. Both personalized phage preparations, where bacteriophages are individually selected for each patient's bacterial isolate, and standardized ready-to-use phage cocktails are considered equally eligible. Applicants are encouraged to develop innovative adaptive trial designs capable of evaluating the full potential of personalized phage therapy, including dynamically updated phage formulations when clinically appropriate.

The scope of the programme extends beyond a single bacterial species or disease. Any difficult-to-treat bacterial infection associated with antimicrobial resistance or biofilm formation is considered eligible, regardless of the route of administration or clinical indication. Particular attention is given to pathogens included in the WHO Bacterial Priority Pathogens List, reflecting the programme's objective of addressing the most urgent global public health threats.

The scientific requirements established by the European Commission are particularly demanding. Clinical protocols must incorporate robust microbiological diagnostics, including phage susceptibility testing when appropriate, standardized manufacturing procedures, detailed characterization of every therapeutic phage used—including genomic sequence, stability and bacterial host range—and clearly defined dosing strategies, treatment duration and administration routes. Applicants are also encouraged to exploit computational modelling, artificial intelligence and innovative experimental models to optimize phage selection, trial implementation and data analysis.

Beyond clinical efficacy, the programme places considerable emphasis on regulatory preparedness. Participating consortia are expected to engage with the European Medicines Agency from the earliest stages of development, define realistic regulatory timelines, and establish comprehensive exploitation strategies covering manufacturing, intellectual property, regulatory approval and eventual commercialization. Rather than supporting isolated academic studies, the programme aims to accelerate the translation of phage therapy into approved medicinal products that can ultimately be integrated into European healthcare systems.

The initiative also reflects a broader vision of responsible biomedical innovation. Projects must comply with FAIR data principles, implement robust GDPR-compliant data protection, consider sex- and gender-related differences where relevant, and actively involve patients, social scientists and humanities experts throughout the research process. This multidisciplinary approach acknowledges that successful implementation of phage therapy will depend not only on scientific and clinical evidence, but also on regulatory acceptance, patient confidence and societal engagement.

Following a highly competitive evaluation process, only three multinational consortia were selected for funding.

REPhRAME, coordinated by Universitätsmedizin Frankfurt in Germany, investigates whether combining bacteriophage therapy with restoration of the intestinal microbiome can prevent recurrent urinary tract infections caused by multidrug-resistant bacteria.

P-PEAKS UTI, coordinated by Unity Health Toronto in Canada, evaluates personalized bacteriophage therapy for women suffering from recurrent Escherichia coli urinary tract infections, with particular emphasis on eliminating bacterial biofilms through precision phage treatment.

PHAGE4DAIR, coordinated by Qeen Biotechnologies in Canada, focuses on early prosthetic joint infections caused by Staphylococcus aureus and evaluates phage therapy administered alongside the DAIR surgical procedure (Debridement, Antibiotics and Implant Retention).

Together, these three projects represent the largest coordinated European investment ever dedicated specifically to generating high-level clinical evidence for bacteriophage therapy. Although they address different infectious diseases and therapeutic strategies, they share a common objective: producing the robust randomized clinical data necessary for regulatory approval and wider clinical adoption.

More broadly, this initiative illustrates the growing transition of phage therapy from experimental medicine toward evidence-based healthcare. As antimicrobial resistance continues to expand worldwide and conventional antibiotics become increasingly ineffective, bacteriophages are no longer viewed simply as an alternative treatment reserved for exceptional cases. Instead, they are progressively becoming part of a broader international effort to develop precision antimicrobial therapies capable of addressing one of the most pressing medical challenges of the twenty-first century.



Sources : 

European Commission – Horizon Europe Work Programme 2025, Topic: "Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections" : https://cordis.europa.eu/programme/id/HORIZON_HORIZON-HLTH-2025-01-DISEASE-01

WHO – Antimicrobial Resistance : https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more